
    
      To evaluate the safety and tolerability of a single subcutaneous injection of ISIS-SGLT2Rx
      administered at four increasing dose levels (50, 100, 200, 400 mg) and to evaluate the safety
      and tolerability of multiple doses of ISIS 388626 administered subcutaneously of either 6 or
      13 weeks.
    
  